The role of PET imaging in lymphoma
- 20 July 2004
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 126 (6) , 772-784
- https://doi.org/10.1111/j.1365-2141.2004.05069.x
Abstract
Positron emission tomography using fluorine-18 (FDG-PET) is increasingly used in the staging and follow-up of malignant lymphomas, although its precise role has not yet been determined. This review considers the results reported at the different stages in the disease history and separately considers the major histological subtypes. Attention is given to the situations in which PET scanning is most likely to influence management. Finally, this review discusses ongoing developments in PET scanning with improved resolution and different radiolabelled tracers.Keywords
This publication has 62 references indexed in Scilit:
- FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients withde novoHodgkin Lymphoma: A Blinded ComparisonLeukemia & Lymphoma, 2004
- Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantationBlood, 2003
- Utility of FDG-PET scanning in lymphoma by WHO classificationBlood, 2003
- Prognostic Significance of 18 F-fluorodeoxyglucose Positron Emission Tomography in LymphomaLeukemia & Lymphoma, 2003
- Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphomaBone Marrow Transplantation, 2002
- FDG PET in the management of lymphoma: a clinical perspectiveEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantationLeukemia, 2002
- Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin's Lymphomas (NHL)Cancer Biotherapy & Radiopharmaceuticals, 2001
- Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?European Journal Of Cancer, 2000
- Positron Emission Tomography with 18-Fluorodeoxyglucose in the Staging and Follow-up of Lymphoma in the ChestActa Oncologica, 1999